designed and synthesized. The newly prepared compounds have been screened for glucose consumption activity in HepG2 cell lines and PPARγ antagonistic activity in HEK293 cell lines. Compound 26g bearing a tetrahydroisoquinolinone scaffold showed the most potent PPARγ antagonistic and hypoglycemic activities. An oral glucose tolerance test (OGTT) was performed and the results further confirmed that 26g was a
已经设计和合成了四个系列的cajanonic acid A (
CAA) 衍
生物。已经筛选了新制备的化合物在 HepG2
细胞系中的
葡萄糖消耗活性和在 HEK293
细胞系中的
PPARγ 拮抗活性。带有
四氢异喹啉酮支架的化合物26g显示出最有效的
PPARγ 拮抗和降血糖活性。进行了
口服葡萄糖耐量试验(OG
TT),结果进一步证实26g是一种有效的降糖药。此外,本研究还研究了
PPARγ 蛋白中化合物26g的可能结合模式。